IN2014DN09418A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09418A
IN2014DN09418A IN9418DEN2014A IN2014DN09418A IN 2014DN09418 A IN2014DN09418 A IN 2014DN09418A IN 9418DEN2014 A IN9418DEN2014 A IN 9418DEN2014A IN 2014DN09418 A IN2014DN09418 A IN 2014DN09418A
Authority
IN
India
Prior art keywords
relates
novel
conjugates
nanocarriers
pdt
Prior art date
Application number
Inventor
Kristian Berg
Anders Høgset
Már Másson
Vivek S Gaware
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of IN2014DN09418A publication Critical patent/IN2014DN09418A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/722Chitin, chitosan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to novel chitosan based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitising agent, and uses thereof in photochemical internalisation (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.
IN9418DEN2014 2012-05-15 2013-05-14 IN2014DN09418A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1208548.6A GB201208548D0 (en) 2012-05-15 2012-05-15 Compound and method
PCT/EP2013/059968 WO2013189663A1 (en) 2012-05-15 2013-05-14 Conjugate of a photosensitiser and chitosan and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN09418A true IN2014DN09418A (en) 2015-07-17

Family

ID=46458880

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9418DEN2014 IN2014DN09418A (en) 2012-05-15 2013-05-14

Country Status (24)

Country Link
US (1) US9901636B2 (en)
EP (1) EP2849791B1 (en)
JP (1) JP6456284B2 (en)
KR (2) KR102269861B1 (en)
CN (1) CN104780941B (en)
AU (1) AU2013279748B2 (en)
BR (1) BR112014028315B1 (en)
CA (1) CA2873259C (en)
DK (1) DK2849791T3 (en)
ES (1) ES2682762T3 (en)
GB (1) GB201208548D0 (en)
HK (1) HK1203850A1 (en)
HR (1) HRP20181276T1 (en)
HU (1) HUE039725T2 (en)
IN (1) IN2014DN09418A (en)
MX (1) MX362237B (en)
NZ (1) NZ630582A (en)
PL (1) PL2849791T3 (en)
PT (1) PT2849791T (en)
RU (1) RU2675830C2 (en)
SG (1) SG11201407603YA (en)
SI (1) SI2849791T1 (en)
WO (1) WO2013189663A1 (en)
ZA (1) ZA201408406B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
EP3129045B1 (en) 2014-04-11 2022-03-02 PCI Biotech AS Method of treating melanoma
KR102678732B1 (en) * 2014-08-28 2024-06-25 피씨아이 바이오테크 에이에스 Compound and method
CN104650259A (en) * 2015-01-23 2015-05-27 广西大学 Nanoporous chitosan quadri(4-sulfophenyl) metalloporphyrin microsphere as well as preparation method and application method of microsphere
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
GB201511159D0 (en) 2015-06-24 2015-08-05 Univ Nottingham Controlled cell delivery vehicle and treatment of tumours
EP3433422B1 (en) * 2016-03-22 2020-11-18 Åbo Akademi University Polysaccharide derivatives as optical brightening agents
KR20190013289A (en) * 2017-08-01 2019-02-11 순천대학교 산학협력단 Nanophotosensitizer comprising water-soluble chitosan
GB201801169D0 (en) * 2018-01-24 2018-03-07 Pci Biotech As Method
CN108892743A (en) * 2018-05-28 2018-11-27 南京工业大学 Nano photosensitizer for photodynamic antibacterial, preparation method and application thereof
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
CN115399328B (en) * 2021-05-27 2024-03-22 中国科学院化学研究所 Polysaccharide-based sterilization material and preparation method and application thereof
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (en) * 1994-09-08 1997-02-26 Photocure As Photochemical method for introducing molecules into the cytosol of cells
GB9905911D0 (en) * 1999-03-15 1999-05-05 Photocure As Method
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
JP2002241307A (en) * 2001-02-19 2002-08-28 Yasuhiko Tabata Active oxygen generating agent for ultrasonic therapy containing photosensitizer
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
GB0415663D0 (en) * 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
WO2007023398A2 (en) 2005-05-16 2007-03-01 Universite De Geneve Compounds for photochemotherapy
JP4287411B2 (en) * 2005-07-01 2009-07-01 株式会社東芝 Virtual memory system and virtual storage method
CN101024087A (en) * 2007-03-28 2007-08-29 长沙理工大学 Chitosan and poly-piptide porphyrinl nano medicine carrier and its preparing and use
KR101035269B1 (en) * 2007-04-23 2011-05-26 한국과학기술연구원 Novel photosensitizer based on pholymer derivatives-photosensitizer conjugates for photodynamic therapy
KR20090047872A (en) 2007-11-08 2009-05-13 인제대학교 산학협력단 Carbohydrate-conjugated chlorins and synthesis thereof
WO2009077908A1 (en) 2007-12-14 2009-06-25 University Of Lausanne Colloidal particle comprising multivalent cyclic anions
KR101076717B1 (en) 2008-11-07 2011-10-26 재단법인대구경북과학기술원 Nanostructure for photodynamic theraphy and fabricating method thereof
US20100129432A1 (en) 2008-11-25 2010-05-27 Taipei Medical University Microorganism-killing combination
KR100918811B1 (en) 2009-04-29 2009-09-25 다이아텍코리아 주식회사 A pharmaceutical composition for treating cancer comprising chlorin e6-folic acid conjugate compound and chitosan
CN101977608A (en) 2009-04-29 2011-02-16 多异亚德韩国株式会社 Pharmaceutical composition comprising chlorine e6-folic acid conjugated compound and chitosan for treatment of cancer
US20120184495A1 (en) * 2009-06-12 2012-07-19 Amrita Vishwa Vidyapeetham University Kerala Targeted nano-photomedicines for photodynamic therapy of cancer
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
KR101228106B1 (en) 2010-01-21 2013-02-01 광주과학기술원 Nanocarriers with Enhanced Skin Permeability, Cellular Uptake and Tumor Targeting
KR101250150B1 (en) * 2010-10-29 2013-04-04 가톨릭대학교 산학협력단 Polymer conjugated photosensitizer for photodynamic therapy and preparation method thereof

Also Published As

Publication number Publication date
JP6456284B2 (en) 2019-01-23
KR20150013803A (en) 2015-02-05
BR112014028315B1 (en) 2022-02-22
ES2682762T3 (en) 2018-09-21
MX2014013516A (en) 2015-11-13
CN104780941A (en) 2015-07-15
ZA201408406B (en) 2016-02-24
HRP20181276T1 (en) 2018-11-16
CN104780941B (en) 2019-01-15
RU2675830C2 (en) 2018-12-25
EP2849791B1 (en) 2018-07-04
CA2873259C (en) 2021-08-03
SI2849791T1 (en) 2018-10-30
RU2014150569A (en) 2016-07-10
JP2015516496A (en) 2015-06-11
NZ630582A (en) 2017-02-24
US20150202293A1 (en) 2015-07-23
WO2013189663A1 (en) 2013-12-27
US9901636B2 (en) 2018-02-27
BR112014028315A2 (en) 2017-10-24
KR20200085380A (en) 2020-07-14
GB201208548D0 (en) 2012-06-27
PL2849791T3 (en) 2019-03-29
DK2849791T3 (en) 2018-08-13
KR102269861B1 (en) 2021-06-28
HUE039725T2 (en) 2019-01-28
HK1203850A1 (en) 2015-11-06
AU2013279748A1 (en) 2014-11-20
CA2873259A1 (en) 2013-12-27
MX362237B (en) 2019-01-09
AU2013279748B2 (en) 2018-08-02
EP2849791A1 (en) 2015-03-25
PT2849791T (en) 2018-10-04
SG11201407603YA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
IN2014DN09418A (en)
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
MX2019010601A (en) Combination therapy for treating cancer.
MX360098B (en) Targeted conjugates encapsulated in particles and formulations thereof.
MX2019001920A (en) Rna for cancer therapy.
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2021008224A (en) Combination of vaccination and inhibition of the pd-1 pathway.
MX2016007351A (en) Combination therapy for treating cancer.
WO2016025635A3 (en) Combination therapy for treating cancer
WO2016145008A3 (en) Mirna for treatment of breast cancer
MX340290B (en) Therapeutic use of a tlr agonist and combination therapy.
WO2012129112A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
MX369664B (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer.
WO2016043874A3 (en) Combination therapy for treating cancer
BR112014001170A2 (en) catheter, especially a permanent catheter, for treating functional problems and / or bladder and / or prostate disease
MX2014005209A (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent.
WO2010151074A3 (en) Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy
MX2013008175A (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof.
MX2018002932A (en) Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer.
MX2021003186A (en) Novel hydrogel conjugates.
MX2015015434A (en) Targeting corroles for tumor toxicity and mri.
MX2022003190A (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative.
WO2013052158A3 (en) Targeted nanovectors and their use for treatment of brain tumors
CY1118118T1 (en) CANNABIDIOL COOPERATIVE TREATMENTS WITH Hypothermia for neuroprotection
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.